Daiichi snaps up Japanese rights to CVD stem-cell therapy – BioPharma Dive
BioPharma-Reporter.com |
Daiichi snaps up Japanese rights to CVD stem–cell therapy
BioPharma Dive Japanese drugmaker Daiichi Sankyo has bought rights to market U.K.-based Cell Therapy’s regenerative heart treatment in Japan, boosting the profile of the stem cell therapy company. Cell Therapy, founded by Nobel Prize-winner Martin Evans, will receive … Daiichi Sankyo licenses off-the-shelf regenerative heart cell therapy from CTL Cell Therapy licenses heart failure therapy in Japan Cell Therapy Ltd’s CEO Ajan Reginald talks to TPL’s Katie Osborne |
Science Daily |
Why lab-made stem cells might fail: Errors in DNA folding
Science Daily Induced pluripotent stem cells hold promise for regenerative medicine because they can, in theory, turn into any type of tissue and because they are made from a patient’s own adult cells, guaranteeing compatibility. However, the technique that turns … Why lab-made stem cells sometimes fail |
|
Stem cell gene therapy for fatal childhood disease ready for human trial
Science Daily Dr Brian Bigger, who leads the Stem Cell and Neurotherapies Laboratory at The University of Manchester and developed the technique in partnership with the Trust scientists said: “This license agreement with Orchard will allow us to take the technique … |
Medical Xpress |
Stem cell gene therapy for fatal childhood disease ready for human trial
Medical Xpress Dr Brian Bigger, who leads the Stem Cell and Neurotherapies Laboratory at The University of Manchester and developed the technique in partnership with the Trust scientists, said: “This license agreement with Orchard will allow us to take the technique … |
European Biotechnology News |
Financing: €21.5m for Oxford stem cell spinout
European Biotechnology News Plans are well advanced for the subsequent launch of OxStem Cardio, OxStem Neuro and OxStem Ocular to apply the stem cell technology to developing therapies for cardiac failure, neurodegenerative diseases, and macular degeneration. The driving force … Oxford University spinoff OxStem gains record funding, big names |